is glp-1 worth it Do The Benefits of Drugs OutWeigh the Negatives? $350 → $245 → $149:

Although meta-analytical data on ketosis in non-T1DM populations are lacking, pharmacovigilance analyses from the FDA Adverse Event Reporting System (FAERS) have indicated a potential signal of ketosis risk in individuals without T1DM receiving GLP-1 RAs without concurrent SGLT2 inhibitors or insulin therapy 27

Mahieu S, Klug M, Millen N, Fabro A, Benmelej A, del Carmen Contini M

Prog Reprod Biol Med 9 : 6167 Akkus E et al

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Panel 2 (Competitive Muscarinic Antagonism): depicts atropine acting as a competitive antagonist at muscarinic acetylcholine receptors, preventing acetylcholine binding and thereby inhibiting parasympathetic signaling